JP5599610B2 - Ｈｓｐ９０の阻害による神経変性疾患の処置 - Google Patents

Ｈｓｐ９０の阻害による神経変性疾患の処置 Download PDF

Info

Publication number
JP5599610B2
JP5599610B2 JP2009518602A JP2009518602A JP5599610B2 JP 5599610 B2 JP5599610 B2 JP 5599610B2 JP 2009518602 A JP2009518602 A JP 2009518602A JP 2009518602 A JP2009518602 A JP 2009518602A JP 5599610 B2 JP5599610 B2 JP 5599610B2
Authority
JP
Japan
Prior art keywords
tau
hsp90
brain
protein
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009518602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542716A5 (enExample
JP2009542716A (ja
Inventor
チオシス、ガブリエラ
グリーンガード、ポール
ドウ、フェイ
ルオ、ウェンジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JP2009542716A publication Critical patent/JP2009542716A/ja
Publication of JP2009542716A5 publication Critical patent/JP2009542716A5/ja
Application granted granted Critical
Publication of JP5599610B2 publication Critical patent/JP5599610B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009518602A 2006-06-30 2007-07-02 Ｈｓｐ９０の阻害による神経変性疾患の処置 Expired - Fee Related JP5599610B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80642706P 2006-06-30 2006-06-30
US60/806,427 2006-06-30
PCT/US2007/072671 WO2008005937A2 (en) 2006-06-30 2007-07-02 Treatment of neurodegenerative diseases through inhibiton of hsp90

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013058040A Division JP5824698B2 (ja) 2006-06-30 2013-03-21 Ｈｓｐ９０の阻害による神経変性疾患の処置

Publications (3)

Publication Number Publication Date
JP2009542716A JP2009542716A (ja) 2009-12-03
JP2009542716A5 JP2009542716A5 (enExample) 2010-09-02
JP5599610B2 true JP5599610B2 (ja) 2014-10-01

Family

ID=38895418

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009518602A Expired - Fee Related JP5599610B2 (ja) 2006-06-30 2007-07-02 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2013058040A Expired - Fee Related JP5824698B2 (ja) 2006-06-30 2013-03-21 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2015174609A Pending JP2016028063A (ja) 2006-06-30 2015-09-04 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2017110721A Expired - Fee Related JP6427227B2 (ja) 2006-06-30 2017-06-05 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2018202024A Expired - Fee Related JP6585266B2 (ja) 2006-06-30 2018-10-26 Ｈｓｐ９０の阻害による神経変性疾患の処置

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013058040A Expired - Fee Related JP5824698B2 (ja) 2006-06-30 2013-03-21 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2015174609A Pending JP2016028063A (ja) 2006-06-30 2015-09-04 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2017110721A Expired - Fee Related JP6427227B2 (ja) 2006-06-30 2017-06-05 Ｈｓｐ９０の阻害による神経変性疾患の処置
JP2018202024A Expired - Fee Related JP6585266B2 (ja) 2006-06-30 2018-10-26 Ｈｓｐ９０の阻害による神経変性疾患の処置

Country Status (8)

Country Link
US (5) US10336757B2 (enExample)
EP (2) EP3305297A1 (enExample)
JP (5) JP5599610B2 (enExample)
AU (1) AU2007269144B2 (enExample)
CA (1) CA2656202C (enExample)
DK (1) DK2034839T3 (enExample)
ES (1) ES2645095T3 (enExample)
WO (1) WO2008005937A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
CN101490052B (zh) * 2006-05-12 2012-08-08 美瑞德生物工程公司 治疗性化合物及其在癌症中的用途
JP5599610B2 (ja) * 2006-06-30 2014-10-01 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０の阻害による神経変性疾患の処置
BRPI0808301B1 (pt) 2007-03-20 2022-05-03 Curis, Inc Composto e composição farmacêutica
CA2705579A1 (en) * 2007-11-14 2009-05-22 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in treating diseases and disorders
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
EP2484371B1 (en) 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
JP2012529535A (ja) 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
WO2011044394A1 (en) 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
AU2013204109B2 (en) * 2009-10-07 2016-05-05 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
EP2694506B1 (en) 2011-04-05 2017-09-20 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
EP2694505B1 (en) * 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
CA2841069C (en) 2011-07-08 2021-11-23 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2014025395A1 (en) * 2012-08-06 2014-02-13 Duke University Compounds and methods for targeting hsp90
RU2644769C2 (ru) 2013-01-23 2018-02-14 Астразенека Аб Химические соединения
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
EA201690406A1 (ru) 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения
EP3035938B1 (en) 2013-09-10 2020-08-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
AU2014386214B2 (en) 2013-12-23 2020-05-21 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
WO2015116774A1 (en) 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Targeted therapeutics
CN106456795A (zh) 2014-03-03 2017-02-22 辛塔医药品有限公司 靶向治疗学
EP3131586A4 (en) 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
BR112017005313A2 (pt) 2014-09-17 2017-12-05 Memorial Sloan Kettering Cancer Center formação de imagem e terapia para inflamação e infecção direcionadas por hsp90
US20180280397A1 (en) 2015-10-05 2018-10-04 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
US11261187B2 (en) 2016-04-22 2022-03-01 Duke University Compounds and methods for targeting HSP90
SI3448382T1 (sl) 2016-04-29 2021-03-31 Orphazyme A/S, c/o COBIS A/S Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo
EP3680241A1 (en) 2017-03-20 2020-07-15 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
AU2018257901A1 (en) * 2017-04-24 2019-11-14 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
JP2020524156A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬を含む併用療法
JP2020524154A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬
AU2018290288A1 (en) * 2017-06-23 2020-01-16 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
HUE072832T2 (hu) 2019-09-19 2025-12-28 Novo Nordisk Healthcare Ag Piruvát kináz R-t (PKR) aktiváló készítmények
WO2022106614A1 (en) 2020-11-19 2022-05-27 Orphazyme A/S Processes for preparing arimoclomol citrate and intermediates thereof
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051702A1 (en) 1997-05-14 1998-11-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
AU2002228771B2 (en) 2000-11-02 2007-10-25 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to HSP90
EP1387678A1 (en) * 2001-05-03 2004-02-11 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
US7553979B2 (en) 2001-11-09 2009-06-30 Conforma Therapeutics Corporation HSP90-inhibiting zearalanol compounds and methods of producing and using same
AU2003207340A1 (en) 2002-02-28 2003-09-09 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
WO2004094647A2 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US20070178537A1 (en) 2003-06-30 2007-08-02 Sloan-Kettering Institute For Cancer Research Assays for detection of bioactive compounds that interact with heat shock protein 90
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7358370B2 (en) 2005-02-25 2008-04-15 Serenex, Inc. Benzene, pyridine, and pyridazine derivatives
WO2006130469A1 (en) * 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
US20110263693A1 (en) 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
CN101490052B (zh) 2006-05-12 2012-08-08 美瑞德生物工程公司 治疗性化合物及其在癌症中的用途
JP5599610B2 (ja) * 2006-06-30 2014-10-01 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０の阻害による神経変性疾患の処置
WO2008013985A2 (en) 2006-07-27 2008-01-31 University Of Florida Use of heat shock activators for tissue regeneration
US20080221132A1 (en) 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
US8580519B2 (en) 2006-11-27 2013-11-12 University Of Maryland, Baltimore Use of plasma HSP90 related to malignancy
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
BRPI0808301B1 (pt) 2007-03-20 2022-05-03 Curis, Inc Composto e composição farmacêutica
EP2183221A1 (en) 2007-07-12 2010-05-12 Crystax Pharmaceuticals S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CA2705579A1 (en) 2007-11-14 2009-05-22 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in treating diseases and disorders
WO2011044394A1 (en) 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
EP2694506B1 (en) 2011-04-05 2017-09-20 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
EP2694505B1 (en) 2011-04-05 2022-04-27 Sloan-kettering Institute For Cancer Research Hsp90 inhibitors
EA201690406A1 (ru) 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения

Also Published As

Publication number Publication date
US20140378452A1 (en) 2014-12-25
US20240158397A1 (en) 2024-05-16
WO2008005937A2 (en) 2008-01-10
AU2007269144B2 (en) 2013-05-16
JP2013177389A (ja) 2013-09-09
EP2034839A4 (en) 2012-08-29
US10336757B2 (en) 2019-07-02
JP2017214379A (ja) 2017-12-07
JP6427227B2 (ja) 2018-11-21
AU2007269144A1 (en) 2008-01-10
EP2034839B1 (en) 2017-08-23
JP5824698B2 (ja) 2015-11-25
ES2645095T3 (es) 2017-12-04
EP3305297A1 (en) 2018-04-11
DK2034839T3 (en) 2017-12-04
JP2019038829A (ja) 2019-03-14
WO2008005937A3 (en) 2008-12-11
EP2034839A2 (en) 2009-03-18
CA2656202C (en) 2018-01-16
JP6585266B2 (ja) 2019-10-02
JP2016028063A (ja) 2016-02-25
US20190389864A1 (en) 2019-12-26
US20230060990A1 (en) 2023-03-02
JP2009542716A (ja) 2009-12-03
US12473288B2 (en) 2025-11-18
US20090298857A1 (en) 2009-12-03
CA2656202A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
JP6585266B2 (ja) Ｈｓｐ９０の阻害による神経変性疾患の処置
Nguyen et al. Cycling at the interface between neurodevelopment and neurodegeneration
JP2009535321A (ja) Ｇｓｋ−３阻害剤としてのｎ−（２−チアゾリル）アミド誘導体
JP2011504474A (ja) アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用
CN107820518B (zh) 用于选择磷酸酶选择性抑制剂和非选择性磷酸酶抑制剂的方法
CN101854924A (zh) 测量wnt活化以及治疗wnt相关癌症的方法和组合物
Hartz et al. Discovery of 2-(anilino) pyrimidine-4-carboxamides as highly potent, selective, and orally active glycogen synthase kinase-3 (GSK-3) inhibitors
Kesavapany et al. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5
CN107969126A (zh) Jnk信号转导通路的细胞穿透肽抑制剂用于治疗轻度认知损害的新用途
EP3177310A1 (en) Compositions and methods for identifying and treating conditions involving hsf1 activity
JP2019501972A (ja) Ｔｄｐ−４３タンパク質症の治療のためのタクロリムス
CN113840922A (zh) Tdp-43的调节剂
AU2017200078C1 (en) Treatment of neurodegenerative diseases through inhibition of Hsp90
HK1253803A1 (en) Treatment of neurodegenerative diseases through inhibition of hsp90
EP2647634A1 (en) Indole-pyrimidine derivatives and their therapeutic uses
EP2970118B1 (en) Compounds for the treatment of neurological disorders
EP2662081A1 (en) Therapeutic use of indole-dihydro-imidazole derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140813

R150 Certificate of patent or registration of utility model

Ref document number: 5599610

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees